A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLCGlobeNewsWire • 09/12/23
NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor CollagenGlobeNewsWire • 09/07/23
Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone DiseaseGlobeNewsWire • 09/05/23
NextCure to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 08/31/23
NextCure Provides Business Update and Reports Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/03/23
NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual MeetingGlobeNewsWire • 06/21/23
NextCure Provides Business Update and Reports First Quarter 2023 Financial ResultsGlobeNewsWire • 05/04/23
NextCure Provides Business Update and Reports Full Year 2022 Financial ResultsGlobeNewsWire • 03/02/23
NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug ConjugatesGlobeNewsWire • 11/15/22
NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual MeetingGlobeNewsWire • 11/07/22
NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 11/03/22
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual MeetingGlobeNewsWire • 10/05/22
NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid TumorsGlobeNewsWire • 10/04/22
NextCure Provides Business Update and Reports Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/04/22
NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory InvestigationGlobeNewsWire • 07/06/22
NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECMGlobeNewsWire • 06/27/22
Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium AnnuaGlobeNewsWire • 06/22/22